A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Dapivirine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASPIRE
  • Most Recent Events

    • 26 Jul 2017 Pooled efficacy results of two independent well-controlled phase III trials of dapivirine vaginal ring (IPM 027 and MTN 020), presented at the 9th International AIDS Society Conference on HIV Science.
    • 26 Jul 2017 Results of a CHARISMA study assessing participants' intimate partner relationships and their partner's interaction with the trial presented at the 9th International AIDS Society Conference on HIV Science
    • 26 Jul 2017 Results assessing impact of intimate partner relationships on adherence to the vaginal ring presented at the 9th International AIDS Society Conference on HIV Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top